Design Therapeutics, Inc. (NASDAQ:DSGN) Q4 2023 Earnings Call Transcript
Design Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.21, expectations were $-0.32.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Logos Capital Arsani William | 4,217,627 | $22,690,833 | -17% | 2.44% |
2. | Baker Bros. Advisors Julian Baker And Felix Baker | 1,743,725 | $9,381,241 | +3% | 0.09% |
3. | Point72 Asset Management Steve Cohen | 1,600,740 | $8,611,980 | +62% | 0.02% |
4. | Tang Capital Management Kevin C. Tang | 1,480,975 | $7,967,646 | 0.56% | |
5. | Almitas Capital Ron Mass | 1,323,667 | $7,121,328 | +6% | 2.51% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$3.74 | 17,809 | 26,965 | 2024-03-25 | Filing | ||
$3.62 | 9,156 | 9,156 | 2024-03-22 | Filing | ||
$3.74 | 1,300 | 1,300 | 2024-03-25 | Filing | ||
$2.35 | 21,000 | Director | 133,024 | 2023-09-29 | Filing | |
$20.00 | 700,000 | Director | 700,000 | 2021-03-30 | Filing |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$4.25 | 814,874 | 0 | 2024-08-09 | Filing | ||
$18.63 | 1,455 | Director | 4,129,950 | 2022-03-22 | Filing | |
$19.01 | 24,000 | Director | 4,131,405 | 2022-03-21 | Filing | |
$20.34 | 13,200 | Director | 4,155,405 | 2022-03-18 | Filing | |
$19.04 | 552,225 | Director | 4,168,605 | 2022-03-18 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 6,526,476 | $17,295,161 | 7.26% | |
2. | 2,380,242 | $6,307,642 | 0% | |
3. | 1,029,478 | $2,728,117 | 2.06% | |
4. | 1,023,723 | $2,712,866 | 0% | |
5. | 997,159 | $2,642,471 | 0% |